Markets don't seem to have fully digested Moody's downgrade of the U.S. credit rating, Mitsubishi UFJ Morgan Stanley ...

Oil futures ended the week on a positive note, lifted mostly by easing trade tensions. Global oil demand growth is expected to be stronger than previously anticipated due to lower oil prices and a ...

In Europe, the Stoxx Europe 600 declined 0.5% in morning trading. BPER Banca rose 4.7% and Monte dei Paschi di Siena added 3.8%. On the other hand, Bank Polska Kasa Opieki slipped 3%, and Powsz Kasa ...

KKR and Stonepeak Partners said they will continue to engage with Assura's board about their 1.61 billion-pound ($2.14 billion) recommended offer for the U.K. healthcare-property investor after ...

Chinese technology giant Xiaomi is slated to introduce a 3-nanometer mobile chip this week and plans to invest nearly $7 billion in chip design over at least 10 years, its founder said.

While robust jobs and wage data have reignited concerns about persistent inflation amid weak productivity growth, some economists still expect the RBA to cut rates in May. Both headline and core ...

Nvidia is deepening its partnerships with Taiwanese companies, including working with Foxconn to build an AI factory supercomputer. The company behind Johnnie Walker whisky, Guinness beer and Smirnoff ...

Dow Jones Top Markets Headlines at 3 AM ET: Stock Futures Fall After Moody’s Downgrade | China’s ... Moody's cited the potential extension of President Donald Trump's 2017 Tax Cuts and Jobs Act, ...

Mohamed El-Erian, the former chief executive of bond giant Pimco and Allianz's chief economic adviser, said the era of U.S. exceptionalism isn't conclusively over.

Home Depot archrival Lowe's Cos. (LOW) also reports during the week. So do off-price chains TJX Companies Inc. (TJX), which ...

Still, focus remains on whether subsidy reforms-especially for fuel-are starting to drive up prices. Moody's Analytics expects headline inflation to edge higher in the second half of the year, partly ...

GSK said combinations of its blood-cancer treatment, Blenrep, have been approved by Japan's Ministry of Health, and that it expects more approvals through the year.